🇺🇸 FDA

Company profile · Sponsor

Aligos

Aligos Therapeutics

ALGS · NYSE biotech SOUTH SAN FRANCISCO, CA, USA
Pipeline
14
Drugs
0
Patents
8

Quick answer

Aligos (ALGS) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ALGS
Exchange NYSE
Company type biotech
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001799448

Pipeline (14)

Search pipeline →

  1. ALG-000184

    Aligos

    Chronic Hepatitis B Infection

    phase 2 small molecule active

    1 trial

  2. ALG-000184, ALG-000184 Placebo, Tenofovir Disoproxil Placebo, Tenofovirdisoproxil Amarox 245 mg Filmtabletten

    Aligos

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  3. ALG-055009

    Aligos

    NASH

    phase 2 small molecule completed

    1 trial

  4. ALG-000184

    Aligos

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  5. ALG-010133

    Aligos

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  6. ALG-020572

    Aligos

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  7. ALG-055009

    Aligos

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  8. ALG-055009

    Aligos

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  9. ALG-097558

    Aligos

    COVID-19

    phase 1 small molecule completed

    3 trials

  10. ALG-125755

    Aligos

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  11. Atorvastatin

    Aligos

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  12. Carbamazepine

    Aligos

    Healthy Volunteer

    phase 1 small molecule active

    1 trial

  13. Pevifoscorvir Sodium (ALG-000184)

    Aligos

    Chronic Hepaititis B Infections

    phase 1 small molecule active

    1 trial

  14. Pevifoscorvir Sodium (ALG-000184)

    Aligos

    Chronic Hepatitis B Infection

    phase 1 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12384779

    Bicyclic compounds

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12252481

    Anti-viral compounds

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12180192

    Modulators of THR-β and methods of use thereof

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12129469

    Modified short interfering nucleic acid (siNA) molecules and uses thereof

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12065428

    Anti-viral compounds

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12018015

    Methods and compositions for targeting PD-L1

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11957683

    Bicyclic compounds

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11952365

    Anti-viral compounds

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Aligos?

Aligos (ALGS) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Aligos sponsor?

We track 14 ClinicalTrials.gov-linked programs for Aligos, including ALG-000184 and 13 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Aligos company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.